Dapagliflozin in Allo-HCT for aGVHD (DAPALAG-01)
Dapagliflozin for Preventing Acute Graft-versus-Host Disease in Allogeneic Hematopoietic Cell Transplantation: A Prospective, Single-Arm Study
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Contact
Study Contact
- Name: Yang XU
- Phone Number: 86-0512-67781850
- Email: xuyang1020@126.com
Study Contact Backup
- Name: Biqi ZHOU
- Phone Number: 86-0512-67781856
- Email: zbq0903@126.com
Study Locations
-
-
Jiangsu
-
Suzhou, Jiangsu, China, 215000
- Recruiting
- The First Affiliated Hospital of Soochow University
-
Contact:
- Yang XU
- Phone Number: 86-0512-67781850
- Email: xuyang1020@126.com
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age 18 to 65 years old.
- Patients with hematologic malignancies indicated for allo-HCT and having a suitable haploidentical or unrelated donor.
- Willing to undergo myeloablative conditioning and graft-versus-host disease prophylaxis base on cyclosporin A and methotrexate.
- With Eastern Cooperative Oncology Group (ECOG) performance status of 0-3.
- Patients with prior use of Dapagliflozin or other hypoglycemic medications may switch to Dapagliflozin, contingent upon the treating physician's assessment of contraindications, will be eligible.
- Signing an informed consent form, having the ability to comply with study and follow-up procedures.
Exclusion Criteria:
- With other malignancies.
- With a previous history of autologous hematopoietic cell transplantation, allo-HCT or chimeric antigen receptor T-cell therapy.
- With a history of allergies to Dapagliflozin.
- With type 1 diabetes or a history of ketoacidosis.
- With a history of recurrent urinary tract infections.
- With severe organ dysfunction.
- With active hepatitis B virus, hepatitis C virus, or human immunodeficiency virus infection.
- In pregnancy or lactation period.
- With any conditions not suitable for the trial (investigators' decision).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Dapagliflozin arm
Participants will take Dapagliflozin10mg every day in -1 to 14 days.
|
Participants will take Dapagliflozin 10mg every day in -1 to 14 days
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Cumulative incidence of grade II-IV aGVHD
Time Frame: 100 days after transplantation.
|
estimated cumulative incidence of grade II-IV aGVHD at 100 days.
|
100 days after transplantation.
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Cumulative incidence of chronic graft-versus-host disease (cGVHD)
Time Frame: 1 year after transplantation.
|
estimated cumulative incidence of cGVHD at 1 year.
|
1 year after transplantation.
|
|
Overall survival
Time Frame: 1 year after transplantation.
|
estimated overall survival at 1 year.
|
1 year after transplantation.
|
|
Graft-versus-host disease-free relapse-free survival (GRFS)
Time Frame: 1 year after transplantation.
|
estimated GRFS at 1 year.
|
1 year after transplantation.
|
|
Cumulative incidence of grade III-IV aGVHD
Time Frame: 100 days after transplantation.
|
estimated cumulative incidence of grade III-IV aGVHD at 100 days.
|
100 days after transplantation.
|
|
Neutrophil reconstitution
Time Frame: up to 30 days.
|
time of neutrophil reconstitution.
|
up to 30 days.
|
|
Platelet reconstitution
Time Frame: up to 100 days.
|
time of platelet reconstitution.
|
up to 100 days.
|
|
Cumulative incidence of relapse
Time Frame: 1 year after transplantation.
|
estimated cumulative incidence of relapse at 1 year.
|
1 year after transplantation.
|
|
Treatment related non-hematological grade 3 or higher adverse events
Time Frame: up to 100 days.
|
Number of unique patients who had a treatment related (possible, probable or definite) non-hematological adverse event that was graded 3 or greater.
|
up to 100 days.
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Estimated)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 2024348
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.